Abstract 77P
Background
Peritoneal sarcomatosis could be observed in patients with retroperitoneal sarcomas. In this study, we aimed to present the role of cytoreductive surgery in the treatment of sarcomatosis.
Methods
Between January 2017-2022, the data of patients who underwent cytoreductive surgery due to peritoneal and retroperitoneal sarcomatosis in a high-volume center was recorded prospectively. The data were analyzed according to the age, gender, place of the lesion, additional organ resections, histopathological analysis, morbidity, mortality, disease-free survival(DFS) and overall survival (OS).
Results
In this 5-year period, 46 patients who were operated due to sarcomatosis were involved in the study. The mean age of the patients was 56 (18-77), 29 (63%) of them female and 17 (37%) of the male. Originally, 31 (67.4%) of the cases originated from retroperitoneal space, 15 (%32.6) of the cases originated intrabdominally. Mean peritoneal carconomatosis index (PCI) score was 12 (3-16). R0 resection was performed in 35 (76%) of the cases, R1 resection was performed in 7 (15.2%) cases, and R2 resection was performed in 4 (8.7%) cases. In the postoperative period within 30 days, mortality was observed in 2 (4,3%) cases. Early period ileus and surgical site infection were the most common mortality reasons. Simultaneous additional organ resections were as follows: colon resection was performed in 14 cases, small intestine resection in 12 cases, splenectomy in 8 cases, distal pancreatectomy in 7 cases, cholecystectomy in and subtotal gastrectomy in 6 cases, vena cava and diaphragm resection in 5 cases, hepatectomy in 4 cases, nefrectomy in 3 cases, salpingoophorectomy in 3 cases and surrenalectomy in 2 cases. 6 (13%) cases were reoperated due to recurrence twice and 3 (6.5%) cases were reoperated for 3 times. Liposarcoma was the most common histopathological type whereas rhabdomyosarcoma, gistosis, fibrosarcoma, angiosarcoma and neurosarcoma were the other types. The median DFS was 12.0 months (95% CI: 7.0-15.0) and the 5-year DFS was 23.9% (95% CI: 14.3-33). 5-year OS of 38.8% (95% CI: 28.2-49.7).
Conclusions
Cytoreductive surgery could be considered in the treatment plan of sarcomatosis in high-volume, experienced tertiary centers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ozgul Duzgun.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.